1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EOM Pharmaceuticals Holdings, Inc.

EOM Pharmaceuticals Holdings, Inc.

IMUC
EOM Pharmaceuticals Holdings, Inc.US flagOther OTC
0.20
USD
+0.08
- -
22.65MMarket Cap
EOM Pharmaceuticals Holdings, Inc.
IMUC
(Other OTC)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
TTM
FRC
- -
- -
- -
- -
8.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-14.33
-236.02
-133.22
-97.6
-76.57
-171.83
-83.35
-112.58
-64.85
-64
-58.67
-78.91
-3.96
-2.41
Basic EPS, GAAP
-5.52
-24.17
-33.61
-62.38
-62.76
-88.89
-94.25
-96.23
-65.08
-68.01
-88.11
-70.99
-3.98
-3.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.42
-247.45
-332.19
-385.08
-428.87
-478.45
-417.78
-335.25
-382.92
-418.64
-340.07
-343.79
-27.78
-35.64
Book Value per Share
1.18
8.69
184.19
93.79
31.98
48.69
47.1
179.17
195.09
158.96
99.63
21.91
1.11
1.04
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-882.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-5
-4
-3
-3
-6
-6
-14
-9
-9
-13
-22
-14
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-875.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1
5
3
1
5
5
26
27
23
22
10
5
3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
5
3
1
2
3
23
26
23
22
6
5
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
2
5
9

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
7
5
4
Cash, Cash Equivalents & STI
7
5
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
1
- -
Payables & Accruals
2
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
56.12%
-19.99%
-24.19%
Free Cash Flow
43%
12.84%
-16.09%
Net Income, GAAP
29.22%
8.23%
-35.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
9.65%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-24.69
-22.95
-15.82
- -
-78.91
2017
-16.7
-11.41
-3.58
- -
-3.96
2018
-0.24
-0.07
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Adial Pharmaceuticals, Inc. (ADIL)
Stealth BioTherapeutics Corp (MITO)
Shanghai Shen Lian Biomedical Corporation (688098.SS)
uniQure N.V. (QURE)
KALA BIO, Inc. (KALA)
Longevity Health Holdings Inc. (XAGEW)
Business
EOM Pharmaceuticals Holdings, Inc. (OTC: IMUC) is a clinical-stage biotechnology company focused on developing novel immunomodulatory and retinal disease therapeutics to treat debilitating inflammatory, viral, and ocular conditions. The company, headquartered in Montvale, New Jersey, operates through its wholly owned subsidiary EOM Pharmaceuticals, Inc. and maintains its pipeline assets including lead candidate EOM613, an investigational peptide-nucleic acid solution immunomodulator with dynamic dual-acting anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects demonstrated in human cell culture studies on monocytes and macrophages; and EOM147, an investigational broad-spectrum aminosterol eye drop formulation with anti-angiogenic activity targeting multiple growth factors such as VEGF, PDGF, and bFGF for retinal diseases including macular edema, offering a non-intravitreal injection alternative. EOM613 has advanced through a Phase 1/2a RESCUE clinical trial in severe COVID-19 patients in Brazil showing reductions in sIL-2R and TNF-alpha cytokines, with prior Phase 2 data indicating benefits in cancer cachexia and plans for upcoming trials in Crohn's disease; EOM147 targets Phase 2 ophthalmic studies. Founded in 2020 following the December 2021 reverse merger with ImmunoCellular Therapeutics, Ltd. where EOM shareholders gained majority control (approximately 96.5%), the company underwent a formal name change from ImmunoCellular Therapeutics, Ltd. in November 2022 and has since shelved Nasdaq uplisting plans while pursuing pipeline advancement amid limited recent funding or partnerships disclosed publicly.

Company News

APIChat

  • defenseworld.net

    EOM Pharmaceutical (OTCMKTS:IMUC) & Siga Technologies (NASDAQ:SIGA) Financial Survey

  • defenseworld.net

    EOM Pharmaceutical (OTCMKTS:IMUC) Trading 139% Higher – Still a Buy?

  • prnewswire.com

    EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

  • prnewswire.com

    EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

  • prnewswire.com

    ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market